DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n

Wednesday 13 April 2016

Mohammed Bajsair

https://media.licdn.com/mpr/mpr/shrinknp_400_400/p/5/005/05d/197/2cc2cf4.jpg.

Mohammed Bajsair

General Manager at Pharmaceutical Solutions Industry

Mohammed Bajsair 
https://www.youtube.com/user/mbajsair1
https://www.facebook.com/mbajsair
https://sa.linkedin.com/in/mohammed-bajsair-829b664


Experience

General Manager

Pharmaceutical Solutions Industry
– Present (5 years 10 months)Jeddah

Commercial Manager

Pharmacuetical Solutions Industry
(5 years 2 months)Jeddah

Marketing Manager

Pharmacuetical Solutions Industry
(2 years 10 months)Jeddah

General dental practitioner

MOH, Saudi Arabia
(5 years)Jeddah



Education

King Saud University

Bachelor's degree, Dentistry





 

 
////////////////

Alexandra Glucksmann, Ph.D., Chief Operating Officer at Editas Medicine Inc.

 
Alexandra Glucksmann, Ph.D., Chief Operating Officer at Editas Medicine Inc.


Alexandra Glucksmann is Chief Operating Officer and founding employee at Editas Medicine Inc., a gene editing company whose mission is to translate its genome editing technology into a novel class of human therapeutics. Previously, Alexandra was Senior Vice President of Research and Development at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products.  Prior to joining Cerulean in 2006, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of science positions with increasing responsibility, ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. She serves on the board of Women in the Enterprise of Science and Technology (WEST). Alexandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago.


 LINKS



 

Background

Ms. Alexandra Glucksmann, PhD. has been Chief Operating Officer at Editas Medicine Inc. since April 2015. Prior to joining Editas Medicine, she served as Senior Vice President of Research and Business Operations at Cerulean Pharma Inc. (formerly, Tempo Pharmaceuticals Inc.) There, she was a founding employee and key contributor to all aspects of building the company, including setting strategy, analyzing product development opportunities, cultivating platform and product partnership prospects, and participating in fundraising activities. Prior to joining Cerulean in 2006, Alexandra spent 13 years at Millennium Pharmaceuticals, which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions with increasing responsibility and was critical in helping Millennium evolve from a genomics research-focused organization to a fully integrated pharmaceuticals company with marketed products. Her division played an integral role in Millennium’s numerous large pharma collaborations, which generated more than $1.8 billion in funding for the company. She serves on the board of directors of Taconic Farms and is the chair of the Board of Women Entrepreneurs in Science and Technology (WEST). She is also a member of the Advisory Council of the Harvard Partners Center for Personalized Genetic Medicine. Ms. Glucksmann was a post-doctoral fellow at the Massachusetts Institute of Technology. Ms. Glucksmann holds as Ph.D. with honors from the University of Chicago.




Alexandra joined Editas Medicine in November 2013 and is the Chief Operating Officer.  Prior to joining Editas Medicine, Alexandra was senior vice president of research and business operations from 2006 until June 2013 at Cerulean Pharma, a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products. There, she was a founding employee and key contributor to all aspects of building the company, including setting strategy, analyzing product development opportunities, cultivating platform and product partnership prospects, and participating in fundraising activities. Prior to joining Cerulean in 2006, Alexandra spent 13 years at Millennium Pharmaceuticals, which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions with increasing responsibility and was critical in helping Millennium evolve from a genomics research-focused organization to a fully integrated pharmaceuticals company with marketed products. Her division played an integral role in Millennium’s numerous large pharma collaborations, which generated more than $1.8 billion in funding for the company. She serves as the chairperson of the Board of Directors of Women Entrepreneurs in Science and Technology (WEST).
Alexandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago and a B.S. in molecular biology from the University of Wisconsin.




Experience

COO

Editas Medicine
– Present (2 years 7 months)

Board of Directors

Taconic
(8 years 10 months)

Senior VP Research and Development

Cerulean Pharma
(6 years 10 months)Cambridge, MA

Senior VP Research & Business Operation

Cerulean Pharma
(5 years)
(Formerly named Tempo Pharmaceuticals)


Education

MIT

Post-doctoral fellow

University of Chicago

PhD Molecular Genetics and Cell Biology








 
////////////

Dr. Jo Viney, Vice President, Immunology Research at Biogen

 
Dr. Jo Viney, Vice President, Immunology Research at Biogen



Dr. Jo Viney is Vice President, Immunology Research at Biogen in Cambridge, MA. In this role, Jo is responsible for setting scientific research direction and strategy with a focus on target identification and validation for drug discovery and development for treating patients with autoimmune and inflammatory diseases. Jo received her PhD from St Bartholomew’s Hospital, University of London in 1991 and pursued postdoctoral fellowships first at the Imperial cancer Research Fund in London, UK, and at Genentech in the Bay Area, California. Following her training, Jo joined Immunex in 1995 and remained at the company, which was acquired by Amgen in 2002, until leaving to join Biogen Idec. Jo has advanced a portfolio of novel biologic and small molecule programs, seven of which have progressed to IND and into clinical development, for diseases such rheumatoid arthritis, asthma, atopic dermatitis, psoriasis, inflammatory bowel disease and lupus. Jo has maintained longstanding membership with the American Society of Immunologists (AAI), the British Society for Immunology (BSI) and the Society for Mucosal Immunology (SMI). She served as President of SMI from 2011-2013. Together with her SMI colleagues, she launched the journal Mucosal Immunology with Nature Publishing Group in 2007. Jo has been a member of the Scientific Advisory Board for Keystone Symposia since 2008, and she partners with KS on a number of programs for under-represented scientists. She is also member of the Scientific Advisory Board for the BioAster Technology Research Institute (IRT) in France, and for Vaxart Inc in the Bay Area. 


 


 LINKS


Experience


Senior Vice President, Drug Discovery

Biogen
– Present (7 months)Cambridge, MA

Vice President, Immunology Research

Biogen Idec
(4 years 3 months)Cambridge, MA

Executive Director, Inflammation Research

Amgen
(8 years 11 months)
Inflammation Research

Staff Scientist, Autoimmunity and Inflammation Research

Immunex
(6 years 10 months)Greater Seattle Area

Postdoc

Genentech
(1 year 7 months)

Postdoc

Imperial Cancer Research Fund
(3 years 4 months)

Education




 .




My particular area of interest revolves around understanding the mechanistic basis of immune homeostasis in organs susceptible to inflammatory disease. Past work has included investigating tolerogenic antigen presentation in the intestine, developing new mouse models of colitis and studying the function of novel butyrophilin-like (BTNL) inhibitory molecules.
I am the vice president of the immunology research group at Biogen. The group’s mission is to develop treatments for underserved immune-mediated inflammatory diseases associated with autoimmunity and fibrosis. Research extends from basic target identification and validation through to drug discovery and preclinical development.

Education

  • Postdoc, Genentech, UK and USA, 1995
  • Postdoc, Imperial Cancer Research Fund, UK, 1994
  • Ph.D., St Bart’s Hospital, University of London, London, UK, 1991

  • B.Sc., University of East London, London, UK, 1987

Selected Publications














////////////

Dr. Rachel Meyers, Senior Vice President, Research at Alnylam Pharmaceuticals

 
Dr. Rachel Meyers, Senior Vice President, Research at Alnylam Pharmaceuticals

Dr. Rachel Meyers is Vice President of Research and RNAi Lead Development (RLD) at Alnylam. In this capacity, she plays a key role in the advancement of Alnylam’s RNAi therapeutic programs, from early discovery through clinical development and her team is responsible for program leadership for most of Alnylam’s preclinical and clinical stage programs. In addition to leading the research organization, Dr. Meyers has worked closely with Alnylam’s business development group, playing an integral part in establishing important collaborations, and has functioned as a scientific lead in collaborations with Novartis, Takeda, Isis, Roche and Genzyme. She also led the scientific diligence resulting in Alnylam’s acquisition of the Sirna assets from Merck. Prior to taking on the leadership of the Research and RLD Groups, Dr. Meyers was one of Alnylam’s Research Directors, focusing her efforts on the development of RNAi therapeutics to target infectious diseases, and was the project lead for the company’s RSV program, where she was responsible for advancing ALN-RSV01 from inception, through pre-clinical development and into the clinic. Dr. Meyers was honored by Mass High Tech as one of 10 Women to Watch 2007 and by R & D Directions as one of its Top 20 Scientists 2007. Before joining Alnylam in April of 2003, Dr. Meyers was a Senior Scientist at Millennium Pharmaceuticals (1999-2003) where she was involved in the bioinformatics, molecular and cell biology of target discovery. Dr. Meyers completed her postdoctoral training at Harvard Medical School in the field of signal transduction, and received her Ph.D. from MIT in the field of in vitro transcription.  She serves as a Scientific Advisor to Editas Medicine.





 Rachel Meyers


 LINKS

 https://www.linkedin.com/in/rachel-meyers-136a8

 https://www.facebook.com/rachel.meyers.7773









Experience

VP Research and RNAi Lead Dev

Alnylam pharmaceuticals
– Present (13 years 1 month)

Post Doc

Harvard Medical School
(4 years)

Research Associate

Genetics Institute
(3 years)


Education





 





////////